Nice

News

Price cut leads NICE to back Novo Nordisk’s obesity drug Sax...

Novo Nordisk’s Saxenda has been recommended by NICE as a treatment for obesity, ending a 10-year drought in new drug therapies for weight management.

Views & Analysis

NICE talking to you: Trends in early HTA engagement

With exclusive data from Freedom of Information (FOI) requests sent to the National Institute for Health and are Excellence (NICE), Leela Barham takes a look at the trend in early engagemen

News

NICE changes stance on Keytruda for first-line head and neck...

As recently as June, NICE was minded not to back routine NHS of MSD’s Keytruda as a first-line treatment for advanced head and n

News

NICE changes its mind on Novartis’ progressive MS drug Mayze...

UK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down earlier this year in draft guidance.

News

Illustration of a nerve cell on a colored background with light effects

Lilly to buy private biotech Disarm Therapeutics for up to $...

Eli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of disease-modifying drugs for neurological diseases, in a deal worth up to $1.36 billion.

News

Scotland backs two myeloma drugs turned down by NICE in Engl...

A north-south divide threatens to emerge in multiple myeloma in the UK, after the Scottish Medicines Consortium (SMC) backed NHS use of two drugs previously turned down by NICE in England.<

Price cut leads NICE to back Novo Nordisk’s obesity drug Sax...

NICE talking to you: Trends in early HTA engagement

NICE changes stance on Keytruda for first-line head and neck...

NICE changes its mind on Novartis’ progressive MS drug Mayze...

Lilly to buy private biotech Disarm Therapeutics for up to $...

Scotland backs two myeloma drugs turned down by NICE in Engl...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Nice

Editor's Picks